Financial PerformanceSLRC reported NOI of $0.45, above the $0.43 estimate, on higher asset yields likely stemming from repayments in its Life Science portfolio.
Investment StrategyManagement sees 'compelling investments' and, with low leverage, views SLRC as being 'positioned very favorably' to take advantage of growth opportunities.
Portfolio QualitySLRC's investment portfolio has many favorable attributes: high quality, first lien, and floating rate, with 78% of its loans in lower-risk, higher-yield specialty commercial finance niches, and only one small non-accrual.